News

Entry forbidden! A new antiviral ISG identified by C. Goujon’s and M. Malim’s teams

Type 1 interferon induces a potent antiviral state through the regulation of hundreds of interferon-stimulated genes (ISGs).

Following interferon treatment, influenza A virus infection is largely inhibited, and the ATIP-Avenir team of Caroline Goujon is interested in understanding the underlying molecular mechanisms. In collaboration with Michael Malim’s lab at King’s College London, they have identified the short isoform of NCOA7 as a new ISG which plays an important role in influenza A virus restriction. CRISPR/Cas9 knock-out of NCOA7 significantly rescues influenza A virus infection in the presence of interferon. Conversely, the ectopic expression of NCOA7 potently inhibits influenza A virus infection. NCOA7 does inhibit the fusion between the viral envelope and the endosomal membrane and therefore the entry of the viral material into the cytoplasm of the target cells. NCOA7 does modulate the pH of the endolysosomal pathway via an interaction with the vacuolar ATPase and, in addition to its antiviral effect, might play a role in regulating antigenic presentation and the adaptive immunity. This work has recently been published in Nature Microbiology.

Tomas Doyle, Olivier Moncorgé, Boris Bonaventure, Darja Pollpeter, Marion Lussignol, Marine Tauziet, Luis Apolonia, Maria-Teresa Catanese, Caroline Goujon* and Michael H. Malim* (* co-senior, co-corresponding authors). The interferon inducible isoform of NCOA7 inhibits endosome-mediated viral entry. Nature Microbiology, in press (http://dx.doi.org/10.1038/s41564-018-0273-9).


     
   

   

Enregistrer

Enregistrer

Enregistrer

Enregistrer

Enregistrer

IRIM
Institut de Recherche en Infectiologie de Montpellier
UMR 9004 - CNRS / UM
1919 route de Mende - 34293 Montpellier cedex 5
FRANCE

 

Enregistrer

Enregistrer

Enregistrer

Enregistrer

Enregistrer

Enregistrer